ISO chemical factory,stable supplying, competitive price
*The following content is generated by AI and is for reference only.
Edoxaban, often referenced in clinical contexts under study codes such as INTS-1, is a potent and selective direct oral anticoagulant (DOAC) belonging to the class of factor Xa inhibitors. Its molecular formula is C24H27ClN6O5S, representing a complex organic structure designed for high specificity in inhibiting the coagulation cascade. The substance does not possess a traditional CAS number because it is primarily an investigational compound or a specific formulation identifier rather than a standalone chemical entity widely cataloged in standard commercial databases; however, the active pharmaceutical ingredient Edoxaban itself carries the CAS Registry Number 850533-79-6.
The primary therapeutic application of Edoxaban is the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of recurrent DVT and PE following initial therapy. Unlike older anticoagulants like warfarin, which require frequent monitoring of prothrombin time, Edoxaban offers a predictable pharmacokinetic profile that typically eliminates the need for routine laboratory monitoring. This characteristic significantly enhances patient compliance and convenience.
Mechanistically, Edoxaban works by directly binding to the active site of factor Xa, thereby blocking the conversion of prothrombin to thrombin and subsequently reducing fibrin formation. This action effectively interrupts the blood clotting process without affecting platelet aggregation directly. Clinical trials have demonstrated its efficacy in reducing thromboembolic events while maintaining a favorable safety profile regarding bleeding risks compared to some alternatives. As a result, it has become a cornerstone therapy in modern cardiovascular medicine, offering a reliable alternative for long-term anticoagulation management in diverse patient populations. The development and refinement of formulations like those investigated under research identifiers ensure continued optimization of dosing strategies to maximize therapeutic benefit while minimizing adverse effects.